Placebo to match sunobinop

Phase 2

Placebo to match sunobinop is one of 10 therapeutic programs targeting Alcohol Use Disorder. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Alcohol Use DisorderCompleted

Alcohol Use DisorderPhase 2

Completed

Competition

Competitive Landscape

11 competitors in Alcohol Use Disorder

#DrugCompanyPhaseTrials

Revia

Teva

Phase 2

6 2

Psilocybin

COMPASS Pathways

Phase 3

7 3

Nimotop

AAzurity Pharmaceuticals

Phase 2

1 4

LY3537031

Eli Lilly

Phase 3

2 5

Aldactone

Pfizer

Phase 1

2 6

Mazdutide

Eli Lilly

Phase 2

1 7

Glucagon-Like Peptide-1 Agonist (GLP-1)

Johnson & Johnson

Phase 2

1 8

Sunobinop

IImbrium Therapeutics

Phase 2

2 9

Placebo to match sunobinop

KKnoa Pharma LLC

Phase 2

1 10

18f-Pf-06445974

NNational Institute of Mental Health (NIMH)

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Alcohol Use Disorder1 trial

A Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Study to Evaluate Impact of Sunobinop (V117957) on Alcohol Craving in Subjects Diagnosed With Moderate to Severe Alcohol Use Disorder and Seeking Treatment

Completed·IImbrium Therapeutics·Phase 2·NCT06545929·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Placebo to match sunobinop. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Placebo to match sunobinop. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Knoa Pharma LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: KKnoa Pharma LLC

Placebo to match sunobinop

Status by Indication[2][1]

Competitive Landscape

Trials by Indication[1]

Alcohol Use Disorder1 trial

References

Drug Info

Quick Facts

Related News